One of the companies to have made significant strides in the field of healthcare over the course of the year so far is Halberd Corporation and it may be a good time to take a closer look into it.
The company was in fact in the news earlier on in the month back on December 6 when it announced that it had received a range of antibiotic-resistant bacteria or ARB from the Centers for Disease Control and Prevention (CDC). The company announced that it was going to deploy its laser eradication technology on the ARB. It should be noted that back on October 18 this year, the company reported that its laser eradication technology had managed to eliminate Gram-Negative bacteria.
Gram-Negative bacteria are well known for being particularly resistant to antibiotics and the latest development could help the company in reinforcing the effectiveness of its technology. The CDC is well-known for providing ARB samples to research organizations so as to promote the development of technologies and methods for the eradication and neutralization of such bacteria.
The Chief Technology Officer of Halberd also spoke about the latest development. He noted that the company had managed to achieve encouraging results when dealing with the Shigella, Salmonella, and E. Coli bacteria. He went on to add that everyone at the company was excited at the possibility of testing of its technology on the latest group of ARB.
On the other hand, the President, Chairman, and Chief Executive Officer of the company, William A Hartman emphasized that the fact that Halberd had been chosen by the CDC was in itself a milestone. He added that it was also an indication that the company’s technology was perhaps of interest to the United States government as well. It will be interesting to see if the Halberd stock gets any traction over the coming days or not.